Recombinant Human PD-L1 (C-mFc)

Recombinant Human PD-L1 (C-mFc)

Size1:10μg price1:$66
Size2:50μg price2:$186
Size3:500μg price3:$1240
SKU: PHH1295 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human PD-L1 (C-mFc)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human Programmed Cell Death 1 Ligand 1 is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a mouse IgG1 Fc tag at the C-terminus.

Accession #

Q9NZQ7

Host

Human Cells

Species

Human

Predicted Molecular Mass

50.9 KDa

Buffer

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Form

Lyophilized

Shipping

The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

Reconstitution

Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

 

Alternative Names

Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1

 

Background

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

 

Note

For Research Use Only , Not for Diagnostic Use.